Mashito 320..327

Sensory nerve activation in airway microvascular permeability in guinea-pig late allergic response

Y. Mashito, M. Ichinose, H. Sugiura, M. Miura, N. Endoh, K. Shirato

Sensory nerve activation in airway microvascular permeability in guinea-pig late allergic First Dept of Internal Medicine, Tohoku response. Y. Mashito, M. Ichinose, H. Sugiura, M. Miura, N. Endoh, K. Shirato. #ERS University School of Medicine, Sendai, Journals Ltd 1999. Japan. ABSTRACT: Because both bradykinin and tachykinins have a potent inflammatory Correspondence: K. Shirato action, these molecules may be involved in the late allergic response. The role of these First Dept of Internal Medicine molecules in airway microvascular permeability during the late allergic response in Tohoku University School of Medicine sensitized guinea-pigs was investigated. 1-1 Seiryo-machi Three weeks after ovalbumin sensitization, the animals were pretreated with Aoba-ku bradykinin B2 receptor antagonist HOE 140, neurokinin 1 receptor antagonist CP Sendai 980-8574 96,345 or vehicle, 30 min before the ovalbumin inhalation challenge. The occurrence Japan of the late allergic response was determined by a two-fold increase in the Fax: 81 227177156 transpulmonary pressure from the baseline values. The microvascular permeability Keywords: Airway inflammation in the trachea was assessed by an index defined as the ratio of the area of vasculature asthma labelled by Monastral blue dye (area density %). bradykinin Significant microvascular permeability and eosinophil accumulation were observed substance P during the late allergic response. Both the bradykinin and substance P concentrations in the bronchoalveolar lavage fluid were increased during the late allergic response. Received: September 15 1998 Pretreatment with HOE 140 suppressed the substance P elevation. Both HOE 140 and Accepted after revision March 8 1999 CP 96,345 also inhibited the airway microvascular permeability during the late allergic response without affecting the eosinophil accumulation in the airways. These findings suggest that bradykinin-mediated sensory nerve activation may play a role in microvascular permeability during the late allergic response in guinea-pigs. Eur Respir J 1999; 14: 320±327.

Bradykinin, a 9-amino acid peptide, is formed from animal models, the late allergic response (LAR) is an plasma precursors as part of the inflammatory response [1, important phenomenon because, during this period, the 2]. Because bradykinin causes vasodilation, airway micro- airways show inflammatory features that are very similar vascular leakage [3], mucus secretion, smooth muscle to those of asthmatic airway inflammation [12, 13]. It has contraction [4] and dyspnoea [5], all of which are the been reported that bradykinin in lavage fluid increases cardinal features of asthma, this molecule may have an during the LAR [14], and that a bradykinin B2-receptor important role in the pathogenesis of asthma. There is antagonist inhibits the bronchoconstriction during that evidence that the concentration of bradykinin is elevated period [15], suggesting the involvement of bradykinin in in the bronchoalveolar lavage fluid (BALF) of asthmatic airway inflammation during the LAR. However, the role subjects [6] and increase after allergen challenge [7]. of the bradykinin-tachykinins pathways in the LAR has Among the endogenous molecules, bradykinin is the not yet been fully examined. most potent stimulant for sensory C-fibres. Airway C-fibre The aim of this study was to elucidate the role of the stimulation may cause the release of tachykinins, such as bradykinin-tachykininspathwayintheairwayinflammatory substance P (SP), into the airways, resulting in neurogenic responses during the LAR. Using sensitized guinea-pigs, inflammation [8, 9]. In fact, in asthmatic airways, brady- the concentrations of bradykinin and SP in the BALF dur- kinin inhalation induced bronchoconstriction and cough ing the LAR were measured. The occurrence of LAR was are largely inhibited by a tachykinin receptor antagonist assessed while monitoring the transpulmonary pressure [10], suggesting that the bradykinin-tachykinins pathway (Ptp) changes. The functional role of bradykinin and tachy- may play a key role in the asthmatic airways. kinins in the LAR were measured using selective brady- In allergic animal models, the role of the bradykinin- kinin B2-andNK1-receptor antagonists, respectively. As an tachykinins pathway has been examined. BERTRAND et al. inflammatory index, the microvascular permeability was [11] have reported that airway microvascular permeabi- measured by means of Monastral blue dye trapping be- lity immediately after allergen challenge is significantly tween the postcapillary venule endothelia, as this site is im- inhibited by both bradykinin B2 and neurokinin 1 (NK1) portant for macromolecular leakage. The accumulation of receptor antagonists, indicating the contribution of the eosinophils into the airways was examined, asthis alsoplays bradykinin-tachykinins pathway during that period. In an important role in the inflammation during the LAR. SENSORY NERVE ACTIVATION IN LAR 321

Table 1. ± Administration of bradykinin B2 (HOE 140) and neurokinin 1 (CP 96,345) receptor antagonists to guinea-pigs to test inhibition of bradykinin- and substance P-induced airway microvascular permeability n555555 Pretreatment Substance Saline Saline HOE 140 DMSO DMSO CP 96,345 Amount 1 mL.kg-1 1mL.kg-1 10 mg.kg-1 1mL.kg-1 1mL.kg-1 50 mg.kg-1 I.v. injection Substance Saline Bradykinin Bradykinin Saline Substance P Substance P Amount 1 mL.kg-1 100 mg.kg-1 100 mg.kg-1 1mL.kg-1 1 mg.kg-1 1 mg.kg-1 DMSO: dimethy sulphoxide.

Methods (table 2). Thirty minutes after the pretreatment, the animals were exposed to saline aerosol (control group) or Animal sensitization 1% OVA aerosol (challenged group) for 1 min using the nebulizer system described above. Two hours after the Male Dunkin-Hartley guinea-pigs (Funabashi Farm, inhalation, all animals were anaesthetized with urethane Sendai, Japan) weighing 350±500 g were used. On day 0 (2 g.kg-1, i.p.). A water filled oesophageal catheter (OD and 1, all animals were sensitized with a subcutaneous 1.52 mm; Natsume Seisahusho, Tokyo, Japan) was injection of 10 mg ovalbumin (OVA) and 100 mg alu- inserted to monitor the Ptp. When the Ptp reached twice minum hydroxide [16]. On day 6, all animals were ex- that of the baseline value in the challenged group (i.e. posed to 2% OVA in saline using an ultrasonic nebulizer when the LAR occurred), at ~4.5±6 h after the inhalation, (NE-U12; Omron, Tokyo, Japan; output 0.8 mL.min-1) the animals were examined as described below. In the for 3 min in a plexiglas exposure chamber (24.5640.5 control group; each experiment was performed at almost 615.0 cm) under spontaneous breathing. All the experi- the same time point during the late phase as in the ments performed in this study were conducted with the challenged animals. The dose of pyrilamine was chosen consent of the Ethics Committee for Use of Experimental according to a previous study [17]. Animals of the Tohoku, University school of medicine.

Quantification of airway microvascular permeability Effectiveness of bradykinin B2 and neurokinin 1 antagonists Monastral blue dye (particle size 20±300 nm) was sonicated for 5 min and filtrated using a 5 mm Millipore The effectiveness of the bradykinin B2-receptor antago- filter (Millipore, Bedford, MA, USA) just before use. One nist HOE 140 and NK1-receptor antagonist CP 96,345 in minute after the administration of Monastral blue dye (30 inhibiting the bradykinin- and SP-induced airway micro- mg.kg-1, i.v.), the thorax was opened and the systemic and vascular permeability, respectively, was tested in six pulmonary circulation perfused with 1% paraformaldehyde groups (table 1). The antagonists or vehicle were admi- (PFA) in 50 mM phosphate buffered saline (PBS), as nistered 6 h before bradykinin or SP injection, and 1 min previously reported [18]. The lungs were then lavaged following the injection the vascular permeability was twice from the cannulated trachea with 5 mL saline to assessed, as described below. measure the bradykinin and SP concentrations as described below. The trachea was removed. The upper part of the trachea was used for eosinophil cell counts and the Effect of bradykinin B2 and neurokinin 1 antagonists lower part was immersed in 1% PFA for 2 h, washed in on the late allergic response distilled water for 2 h and soaked in glycerol for 20 h at room temperature, followed by dehydration in 100% eth- On day 21, the animals were pretreated with pyrilamine anol for 1 h at room temperature. The tissue was im- (10 mg.kg-1, i.p.) to prevent the animals from dying during mersed in toluene for 1.5 h, then in 100% ethanol for 1 h, the early phase airway response [17]. HOE 140 (s.c.), CP and hydrated in distilled water for 2 h at room tem- 96,345 (i.p.) or the vehicle thereof were also injected perature. The hydrated trachea was opened longitudinally

Table 2. ± Administration of bradykin B2 (HOE 140) and neurokinin 1 (CP 96,345) receptor antagonists to sensitized guinea-pigs to test effect on the late allergic response HOE 140 n55555 Pretreatment s.c. Saline Saline HOE 140 HOE 140 HOE 140 (1 mL.kg-1)(1mL.kg-1) (0.1 mg.kg-1)(1mg.kg-1) (10 mg.kg-1) Challenge Saline OVA OVA OVA OVA CP 96,345 n555 Pretreatment s.c. DMSO DMSO CP 96,345 (1 mL.kg-1)(1mL.kg-1) (50 mg.kg-1) Challenge Saline OVA OVA DMSO: dimethy sulphoxide. 322 Y. MASHITO ET AL. along the ventral midline and flattened between two and 2% activated charcoal in assay buffer) was added to glass slides held together by clips for 24 h in 100% the reaction mixture and centrifuged at 2,0006g,48C, for ethanol at room temperature, cleared in toluene for 15 10 min. The radioactivity of the supernatant was measured min, and mounted on a glass slide. Five images of the by a gamma counter (Model 5420A; Packard Instrument intercartilaginous portion from each tracheal preparation Co., Meriden, CT, USA). In this system, the sensitivity of were viewed with image analysing software (MacScope; detection of SP in saline was 1±60 fmol.mL-1. Mitani Co., Fukui, Japan) using an Apple Macintosh computer (Apple Computer Inc., Cupertino, CA, USA) connected to the microscope. The Monastral blue dye Quantification of eosinophil accumulation into the air- trapped between the endothelia was quantified as the area ways density [19], that is, the percentage area of mucosa occupied by vessels stained with Monastral blue in a site The upper part of the trachea was immersed in 10% just proximal to the carina. formalin for 3 days, before being embedded in paraffin and sectioned at a thickness of 4 mm.Thesectionswere immersed in Hansel's stain solution for 30±45 s, followed Measurement of bradykinin and substance P concen- by the addition of a drop of distilled water for a further 30 trations in bronchoalveolar lavage fluid s. The slides were then flooded with distilled water followed by 95% methyl alcohol. The slides were then Because bradykinin and SP are decomposed by angio- drained [20]. Eosinophils were counted in both the epithe- tensin converting enzyme (ACE) or neutral endopeptitase lial layer and submucosal area using a microscope. (NEP) in only a few minutes, the BALF was boiled immediately in order to inactivate these enzymes. The BALF was then stored at -808C until assay. The bradykinin and SP concentrations were quantified by radioimmu- Drugs noassay (RIA). The BALF samples (1 mL) for bradykinin were mixed with isopropylalcohol (2.5 mL) and cen- HOE 140 and CP 96,345 were kindly donated by trifuged at 12006g,48C for 10 min. The supernatant was Hoechst AG (Frankfurt, Germany) and Yamanouchi Phar- mixed with petroleum ether (2 mL) and the upper layer maceutical Co. Ltd. (Tukuba, Japan), respectively. Brady- was aspirated, and this step being performed twice. The kinin, Monastral blue dye, OVA, pyrilamine and urethane lower layer was evaporated by nitrogen gas at 558C, mixed were from Sigma Chemical Co. (St. Louis, MO, USA). SP with tris-hydroxymethy-amino methane (Tris)-HCl buffer was from Funakoshi Co. (Tokyo, Japan). Aluminum (500 mL, pH 7.0) and centrifuged at 12006g,48Cfor5 hydroxide, dimethyl sulphoxide (DMSO) and paraformal- min. The sample (400 mL) or bradykinin standard (Peptide dehyde were from Wako Pure Chemical Industries (Osaka, Institute, Inc., Osaka, Japan) was mixed with anti-bra- Japan). Hansel's stain solution was from Torii Chemical dykinin (100 mL; SRL Inc., Tokyo, Japan) and stored Co. (Tokyo, Japan) Saline was from Ohtsuka Chemical Co. overnight at 48C. They were incubated with 100 mL[125I- (Tokyo, Japan). tyr8]-bradykinin (Du Pont NEN Research Products, Boston, MA, USA) at 48C for 4 h. The mixtures were mixed with 1% c-globulin (100 mL) and 25% polyethylene Statistical analysis glycol (700 mL), and centrifuged at 12006g,48Cfor10 min to separate the antibody-bound form from the free Data are expressed as meanSEM. Multiple comparisons peptide. The supernatant was discarded, and the radio- of mean data of dye extravasation and quantification of activity of the sediment was measured by a gamma counter eosinophils among the groups were performed by one way (1261 Multi Gamma; Wallac Oy, Turku, Finland). analysis of variance (ANOVA), followed by Scheffe'stest The BALF samples for SP were diluted with 4% acetic as a post hoc test. Comparisons of mean data of bradykinin acid pH 4.0 to a final volume of 50 mL, homogenized and SP concentration in BALF among the groups were using Polytron PT-10 (Kinematica AG, Littau, Switzer- performed by the Mann-Whitney U-test. A p-value <0.05 land), and centrifuged at 40,0006g for 30 min. The super- was considered significant. natant was loaded onto reversed-phase C18 cartridges (Sep-Pak C18; Millipore Co., Milford, MA. USA). After washing with 20 mL of 4% acetic acid pH 4.0 and 20 mL distilled water, SP was eluted with 2 mL of 80% ace- Results tonitrile in 0.1% trifluoroacetic acid. Eluates were con- centrated by spin-vacuum evaporation, lyophylized, and the eluates dissolved using 0.15 mL of assay buffer (50 Bradykinin B2- and neurokinin 1-receptor antagonists ef- mm phosphate buffer, pH 7.2, containing 3.7 mg.mL-1 fect on bradykinin- and SP-induced airway microvascular ethylene diamine tetra-acetic acid (EDTA) and 0.5% permeability bovine serum albumin (BSA)) before being subjected to an RIA for SP. RIA for SP was performed using 125I±SP Bradykinin administration caused significant airway (Amersham International plc., Amersham, UK) and anti- microvascular permeability. This response was completely SP rabbit serum (Amersham International plc). A 0.1 mL inhibited by HOE 140 pretreatment (fig. 1a). SP also sample was mixed with 0.5 mL assay buffer, 0.1 mL showed significant airway microvascular permeability, antiserum and 0.1 mL 125I-SP, and stored at 48C for 24 h. A and this response was almost completely abolished by CP total of 0.2 mL dextran/charcoal suspension (0.2% dextran 96,345 (fig. 1b). SENSORY NERVE ACTIVATION IN LAR 323 a) 20 * b)

10 **

Monastral blue area density % # 0 S/S S/B HOE/B DMSO/ DMSO/ CP/SP S SP Fig. 1. ± a) Effect of the bradykinin B2-receptor antagonist (HOE 140; 10 mg.kg-1, s.c.) on bradykinin-induced airway microvascular permeability. S/S: Saline treated, saline injected group; S/B: saline treated, bradykinin injected group; HOE/B: HOE 140 treated, bradykinin injected group. *: p<0.01, compared with the S/S group; #:p<0.01, compared with the S/B group. b) Effect of neurokinin 1 receptor antagonist (CP 96,345; 50 mg.kg-1, i.p.) on substance P (SP)-induced airway microvascular permeability. DMSO/S: dimethyl sulphoxide (DMSO) treated, saline injected group; DMSO/SP: DMSO treated, SP injected group; CP/ SP: CP 96,345 treated, SP injected group. **: p<0.01, compared with the DMSO/S group; ##:p<0.01, compared with the DMSO/SP group. All values are meanSEM.

Bradykinin concentration in bronchoalveolar lavage fluid during the late allergic reaction

All animals showed a rapid breathing pattern and cyanosis during and immediately after OVA inhalation. About 45 min later, the animals' breathing pattern returned to the level of the pre-inhalation challenge. At 4.5±6 h after the inhalation, the Ptp values rose to twice that of the baseline values in OVA challenged but not in saline exposed animals. OVA challenge caused a significant increase in the Fig. 3. ± Representative view of Monastral blue labelled airway micro- -1 vessels during the late allergic response in a) saline treated, saline ex- bradykinin concentration in the BALF (10583 pg.mL , posed and b) saline treated, ovalbumin challenged animals. (Internal p<0.05) compared with those of the saline exposed animals scale bar=300 mm.) (1.81.1 pg.mL-1) during the LAR (fig. 2).

those of the saline treated-saline exposed group during the Effect of bradykinin B -receptor antagonist LAR (fig. 3). Monastral blue dye trapping was observed 2 at the vessels of 10±20 mm in width, which is compatible OVA challenge caused remarkable Monastral blue dye with the size of postcapillary venules [18]. The effects of extravasation in the saline treated animals compared with HOE 140 are summarized in figure 4. HOE 140 pretreatment significantly inhibited the OVA-induced airway microvascular permeability in a dose-dependent manner. 200 + Figure 5 shows a representative view of eosinophil accumulation in the saline exposed and OVA challenged groups during the LAR. OVA inhalation caused a sig- -1 150 nificant eosinophil accumulation both in the epithelium (1.50.9±12.92.0 cells.100 mm epithelium-1,p<0.01) . 2 100 and submucosa (2.21.2±23.62.9 cells 10,000 mm submucosa-1,p<0.01) during the LAR compared with the saline exposed group. HOE 140 pretreatment did not affect the eosinophil accumulation (fig. 6). Bradykinin pg·mL 50 The relationship between bradykinin and SP during the LAR was then investigated. In the saline treated animals, 0 OVA challenge caused a significant increase in the SP Saline OVA concentration in the BALF compared to the saline treated, Fig. 2. ± Bradykinin concentrations in the bronchoalveolar lavage fluid. saline exposed animals during the LAR (fig. 7). HOE 140 During the later allergic responses of the animals (LAR) after ovalbumin (OVA) inhalation or saline inhalation at a time matched to the LAR. All pretreatment reduced the SP concentration in the BALF + values are meanSEM. :p<0.05, compared with the saline exposed group. in a dose-dependent manner. 324 Y. MASHITO ET AL.

20 *

* 10

$ 5 $$ Monastral blue area density % 0 S/S S/OVA Hoe(0.1)/ Hoe(1)/ Hoe(10)/ OVA OVA OVA

Fig. 4. ± Effect of the bradykinin B2-receptor antagonist (HOE 140) on airway microvascular permeability during the late allergic response. S/S: Saline treated, saline challenged group; S/OVA: saline treated, ovalbumin (OVA) challenged group; HOE(0.1)/OVA, HOE(1)/OVA, HOE (10)/OVA: HOE 140 (0.1, 1 or 10 mg.kg-1) treated, OVA challenged group. All values are meanSEM.*:p<0.01, compared with the S/S group; $:p<0.05, $$:p<0.01, compared with the S/OVA group.

Effect of neurokinin 1-receptor antagonist

OVA challenge caused significant Monastral blue dye extravasation in the DMSO-treated animals compared with the DMSO-treated, saline exposed group during the LAR (fig. 8). CP 96,345 pretreatment almost completely inhibited the dye extravasation. Figure 9 shows the effects of CP 96,345 on eosinophil accumulation during the LAR. CP 96,345 pretreatment did not show an in- Fig. 5. ± Eosinophil accumulation within the airway wall during the hibitory effect on eosinophil accumulation. late allergic response. a) In the saline treated, saline exposed animals, few eosinophils were seen. b) Many more eosinophils accumulated both in the epithelium and submucosa in the saline treated, ovalbumin challenged animals. (Internal scale bar=20 mm.) Discussion other is an indirect mechanism that involves tachykinin These data show that allergen inhalation causes release [22, 23]. In the present study, the bradykinin B2- significant airway microvascular permeability and eosino- receptor antagonist-induced reduction in the SP concen- phil accumulation into the airway during the LAR. During tration in the BALF was in parallel with the inhibition of this period, both the bradykinin and SP concentrations in microvascular permeability. Therefore, during the LAR, the BALF were increased. Furthermore, each bradykinin bradykinin seems to cause airway microvascular permeability via tachykinin release. B2 and NK1 receptor antagonist significantly inhibited the airway microvascular permeability during the LAR. These In the airways, tachykinins are thought to be released results suggest that the bradykinin-tachykinins pathway, from sensory C-fibres via axon reflex mechanisms [9, 10]. that is sensory nerve activation, plays an important role in Among the endogenous molecules, bradykinin is one of microvascular permeability during the LAR in sensitized the most potent stimulators of C-fibres [3, 21]. Tachy- guinea-pigs. kinins cause airway microvascular leakage via activation Bradykinin is formed from kininogens by the action of of NK1 receptors in the endothelial cells of post capillary plasma and tissue kallikrein [2, 21]. In allergen inhalation venules [18, 24]. In the present study, the NK1 receptor challenge, it has been reported that both plasma and tissue antagonist CP 96,345 completely inhibited the airway kallikrein release and/or activation occurs [7]. ERJEFAÈ LT et microvascular permeability during the LAR, strongly al. [14] have also reported that the bradykinin concentra- suggesting that NK1 receptor activation in the endothelial tion increases during the LAR, which is in agreement cells and the resulting contraction of the cells are the final with the present results. Bradykinin has a variety of steps that lead to the airway microvascular permeability airway actions including airway smooth muscle contrac- during the LAR in guinea-pigs. tion, hypersecretion and microvascular permeability via In asthmatic animal models, allergen challenge causes bradykinin B2 receptors [3, 21], and is thought to be an immediate and late airway responses [12, 13]. The imme- important mediator in asthmatic airway inflammation diate phase response is mainly via airway smooth muscle [21]. Bradykinin-induced airway microvascular perme- contraction mediated by mast cell-derived mediators ability has been reported to occur via two pathways. One including histamine and leukotrienes. On the other hand, pathway is its direct action in the endothelium and the the late phase response is due to airway inflammation SENSORY NERVE ACTIVATION IN LAR 325

a) 20 20 -1 * * *

15 -1

m epithelium *

µ 10 10 + $ SP fmol·mL SP

5 $$ $$

Eosinophils·100 0 0 S/S S/OVA HOE(0.1)/ HOE(1)/ HOE(10)/ OVA OVA OVA b) Fig. 7. ± Effect of the bradykinin B2-receptor antagonist (HOE 140) on -1 40 substance P (SP) concentration in the BALF of guinea-pigs during the late allergic reaction. S/S: Saline treated, saline challenged group; S/ * OVA: saline treated, ovalbumin (OVA) challenged group; HOE(0.1)/ OVA, HOE(1)/OVA, HOE (10)/OVA: HOE 140 (0.1, 1 or 10 mg.kg-1) 30 * * * treated, OVA challenged group. All values are meanSEM.*:p<0.01, submucosa $ $$ 2 compared with the S/S group; :p<0.05, :p<0.01, compared with S/

m OVA group. µ 20 mechanisms of airway microvascular permeability and eosinophil accumulation seem to be different. The brady- 10 kinin-tachykinins pathway may not work in the largest postcapillary venules nor be invo1ved in the cytokine, adhesion molecule and chemokine systems. Eosinophils·10000 0 S/S S/OVA HOE(0.1)/ HOE(1)/ HOE(10)/ Monastral blue dye was used to assess the airway OVA OVA OVA microvascular permeability. The particles of Monastral Fig. 6. ± Effect of the bradykinin B2-receptor antagonist (HOE 140) on blue are too large to cross the endothelium of tracheal eosinophil infiltration during the late allergic response in the a) epi- blood vessels with a normal permeability. However, when thelium and b) submucosa. S/S: Saline treated, saline challenged group; S/OVA: saline treated, ovalbumin (OVA) challenged group; HOE(0.1)/ the blood vessels become more permeable, possibly due to OVA, HOE(1)/OVA, HOE (10)/OVA: HOE 140 (0.1, 1 or 10 mg.kg-1) the endothelial contraction, the dye passes through gaps in + treated, OVA challenged group. All values are meanSEM. :p<0.05, *: the endothelium and is trapped by the basal lamina where it p<0.01, compared with the S/S group. remains and thus labels the site of extravasation [18, 24, 28]. such as airway wall oedema and mucus secretion [12, 13], In conclusion, these results have demonstrated that both which is very similar to asthmatic chronic airway inflam- bradykinin B2-andNK1-receptor antagonists almost mation. To elucidate the inflammatory mechanisms, ani- completely inhibited the airway microvascular permeabil- mal models including guinea-pigs [14], rats [25, 26] and ity but not the eosinophil accumulation during the late dogs [27] have been developed using vascular perme- allergic reaction. Airway microvascular permeability is an ability as the marker of inflammation. The present study is the first report showing that the bradykinin-tachykinins 20 ** pathway, that is sensory nerve activation, is a major contributor to airway microvascular permeability, which has a key role in airway wall oedema during the LAR. 15 In the present study, both bradykinin B2-andNK1 receptor antagonists almost completely inhibited the airway microvascular permeability during the LAR. In 10 contrast, eosinophil accumulation into the airway during this period was not affected by the antagonists. Micro- vascular permeability has been reported to be mainly due 5 ‡ to endothelial contraction in the smallest postcapillary

venules [18, 28]. Both bradykinin and SP are potent Monastral blue area density % inducers of permeability. Previously, it has been reported 0 that bradykinin-induced tracheal microvascular perme- DMSO/S DMSO/OVA CP/OVA ability is largely reduced by NK1-receptor antagonists Fig. 8. ± Effect of the neurokinin 1 receptor antagonist (CP 96,345) on [22], which is compatible with the present results. On the airway microvascular permeability during the late allergic response. other hand, eosinophil recruitment into the airways occurs DMSO/S: dimethyl sulphoxide (DMSO) treated, saline challenged group; in the largest postcapillary venules [18, 29] and is mainly DMSO/OVA: DMSO treated, ovalbumin (OVA) challenged group; CP/ OVA: CP 96,345 treated, OVA challenged group. All values are mean { regulated by chemical factors including cytokines, ad- SEM. **: p<0.01, compared with the DMSO/S group; :p< 0.01, compared hesion molecules and chemokines. Thus, the site and with the DMSO/OVA group. 326 Y. MASHITO ET AL.

a) ral mechanisms. J Pharmacol Exp Ther 1990; 253: 594± 20 599.

-1 5. Fuller RW, Dixon CMS, Cuss FMC, Barnes PJ. Brady- kinin-induced bronchoconstriction in humans: mode of action. Am Rev Respir Dis 1987; 135: 176±180. ** 6. Christiansen SC, Proud D, Cochrane CG. Detection of ** tissue kallikrein in the bronchoalveolar lavage fluid of

m epithelium asthmatic subjects. J Clin Invest 1987; 79: 188±197. µ 10 7. Christiansen SC, Proud D, Sarnoff RB, Juergens U, Cochrane CG, Zuraw BL. Elevation of tissue kallikrein and kinin in the airways of asthmatic subjects after endo- bronchial allergen challenge. Am Rev Respir Dis 1992; 145: 900±905. 8. Lundberg JM, Saria A. Capsaicin-induced desensitization Eosinophils·100 0 of airway mucosa to cigarette smoke, mechanical and chemical irritants. Nature 1983; 302: 251±253. b) 9. Barnes PJ. Asthma as an axon reflex. Lancet 1986; 1:

-1 30 242±245. 10. Ichinose M, Nakajima N, Takahashi T, Yamauchi H, ** ** Inoue H, Takishima T. Protection against bradykinin-induced bronchoconstriction in asthmatic patients by neurokinin receptor antagonist. Lancet 1992; 20: 1248±1251. submucosa 20 2 11. Bertrand C, Nadel JA, Yamawaki I, Geppetti P. Role of m

µ kinins in the vascular extravasation evoked by antigen and mediated by tachykinins in guinea pig trachea. J Immunol 1993; 151: 4902±4907. 10 12. Sheth KK, Lemanske Jr RF. The early and late asthmatic response to allergen. In: Busse WW, Holgate ST, eds. Asthma and Rinitis. Boston, Blackwell Scientific Publi- cations, 1995; pp. 946±960.

Eosinophils·10000 0 13. Lemanske Jr RF, Kaliner MA. Late phase allergic re- DMSO/S DMSO/OVA CP/OVA actions. In: Middleton E Jr, Reed CE, Ellis EF, Adkinson Fig. 9. ± Effect of the neurokinin 1 receptor antagonist (CP 96,345) on NF Jr, Yunginger JW, Busse WW, eds. Allergy Principles eosinophil infiltration during the late allergic response in the a) epi- and Practice, 4th Edn. St. Louis, The C.V. Mosby thelium and b) submucosa. DMSO/S: dimethyl sulphoxide (DMSO) Company, 1993; pp. 320±361. treated, saline challenged group; DMSO/OVA: DMSO treated, ovalbumin (OVA) challenged group; CP/OVA: CP 96,345 treated, OVA 14. ErjefaÈlt I, Greiff L, Alkner ULF, Persson CGA. Al- challenged group. All values are meanSEM. **: p<0.01, compared with lergen-induced biphasic plasma exudation responses in the DMSO/S group. guinea pig large airways. Am Rev Respir Dis 1993; 148: 695±701. important factor of airway inflammation in asthma [30± 15. Abraham WM, Burch RM, Farmer SG, Sielczak MW, 33]. Further, neutral endopeptidase, which is responsible Ahmed A, Cortes A. A bradykinin antagonist modifies for the degradation of both bradykinin and tachykinins, is allergen-induced mediator release and late bronchial re- mainly localized in airway epithelial cells [34]. Because sponses in sheep. Am Rev Respir Dis 1991; 143: 787±796. airway epithelial shedding is frequently observed in 16. Andersson P. Antigen-induced bronchial anaphylaxis in actively sensitized guinea-pigs. Pattern of response in asthmatic airways, exaggerated sensory nervous pathway relation to immunization regimen. Allergy 1980; 35: 65± via inactivation of the peptide may have a key role [9]. 71. Therefore, inhibition of the bradykinin-tachykinins path- 17. Noonan TC, Gundel RH, Desai SN, et al. The effects of way may become useful for asthma treatment in the an anti-CD18 antibody (R15.7) in antigen-induced airway future. hyperresponsiveness (AH) and cell influx in guinea pigs. Agents Actions 1991; 34: 211±213. Acknowledgement. The authors thank B. Bell 18. McDonald DM. Endothelial gaps and permeability of for reading the manuscript. venules in rat tracheas exposed to inflammatory stimuli. Am J Physiol 1994; 266: L61±83. References 19. Umeno E, McDonald DM, Nadel JA. Hypertonic saline increases vascular permeability in the rat trachea by 1. Proud D, Kaplan AP. Kinin formation: mechanisms and producing neurogenic inflammation. J Clin Invest 1990; role in inflammatory disorders. Ann Rev Immunol 1988; 85: 1905±1908. 6: 49±83. 20. Hansel FK. The cytology of the secretions in allergy. In: 2. Regoli D, Barabe J. Pharmacology of bradykinin and Clinical Allergy. St. Louis, The C.V. Mosby Company, related kinins. Pharmacol Rev 1980; 32: 1±46. 1953; pp. 408±419. 3. Ichinose M, Barnes PJ. Bradykinin-induced airway mic- 21. Barnes PJ, Chung KF, Page CP. Inflammatory mediators rovascular leakage and bronchoconstriction are mediated and asthma. Pharmacol Rev 1988; 40: 49±84. via a bradykinin B2 receptor. Am Rev Respir Dis 1990; 22. Nakajima N, Ichinose M, Takahashi T, et al. Bradykinin- 142: 1104±1107. induced airway inflammation. Contribution of sensory 4. Ichinose M, Belvisi MG, Barnes PJ. Bradykinin-induced neuropeptides differs according to airway site. Am J Res- bronchoconstriction in guinea pig in vivo: role of neu- pir Crit Care Med 1994; 149: 694±698. SENSORY NERVE ACTIVATION IN LAR 327

23. Lundberg JM, Salia A, Brodin E, Russell S, Forkers K. A chea. I. Changes in venules, leucocytes and epithelial substance P antagonist inhibits vagally induced increase cells. J Neurocytol 1988; 17: 583±603. in vascular permeability and bronchial smooth muscle 29. Baluk P, Bertrand C, Geppetti P, McDonald DM, Nadel contraction in guinea-pig. Proc Natl Acad Sci USA. 1983; JA. NK1 receptors mediate leukocyte adhesion in neuro- 80: 1120±1124. genic inflammation in the rat trachea. Am J Physiol 1995; 24. Baluk P, Hirata A, Thurston G, et al. Endothelial gaps: 268: L263±269. time course of formation and closure in inflamed venules 30. Persson CGA. Plasma exudation and asthma. Lung 1988; of rats. Am J Physiol 1997; 272: L155±170. 166: 1±23. 25. Bolton PB, Lefevre P, McDonald DM. Salmeterol reduces 31. McFadden ER Jr. Hypothesis: exercise-induced asthma as early and late-phase plasma leakage and leukocyte adhe- a vascular phenomenon. Lancet 1990; 335: 880±883. sion in rat airways. Am Rev Respir Dis 1997; 155: 1428± 32. Yager D, Shore S, Drazen M. Airway luminal liquid: 1435. sources and role as an amplifier of bronchoconstriction. 26. Baluk P, Bolton PB, Hirata A, Thurston G, McDonald Am Rev Respir Dis 1991; 143: S52±54. DM. Endothelial gaps and adherent leukocytes in aller- 33. Kimura K, Inoue H, Ichinose M, Miura M, et al. Brady- gen-induced early- and late-phase plasma leakage in rat kinin causes airway hyperresponsiveness and enhances airways. Am J Pathol 1998; 152: 1463±1476. maximal airway narrowing. Role of microvascular leak- 27. Ohrui T, Sekizawa K, Aikawa T, Yamauchi K, Sasaki age and airway edema. Am Rev Respir Dis 1992; 146: H, Takishima T. Vascular permeability and airway nar- 1301±1305. rowing during late asthmatic response in dogs treated 34. Sekizawa K, Tamaoki J, Graf PD, Basbaum CB, Borson with metopirone. J Allergy Clin Immunol 1992; 89: 933± DB, Nadel JA. Enkephalinase inhibitor potentiates mam- 943. malian tachykinin-induced contraction in ferret trachea. J 28. McDonald DM. Neurogenic inflammation in the rat tra- Pharmacol Exp Ther 1987; 243: 1211±1217.